Ruxolitinib for Myelofibrosis Patients Throughout Stem Cell … : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
eir firing with most being inhibited by contralateral noxious stimulation. Optical inhibition and activation of unilateral SIIGlu reduced and enhanced bilateral nociceptive sensitivity, respectively, without…
CISNET is a consortium of NCI-sponsored investigators that use statistical modeling to improve our understanding of cancer control interventions in prevention, screening, and treatment and…
Cancer Research Early Career Award | Cancer Research | American Association for Cancer Research .aacrcontent .banner{ width: 100% margin: -20px; } .aacrcontent .banner-sm{ display: none;…
A pivotal phase 2 study evaluating glecirasib for the treatment of KRAS G12C-mutated advanced non-small cell lung cancer met its primary end point with an…
Individuals with low-risk chronic lymphocytic leukemia who exhibit no symptoms may no longer require specialized follow-up, according to study data published in Blood Advances.The findings…
Introduction At a recent conference, Dr. Anjali Advani of the Cleveland Clinic discussed the transformative role of Chimeric Antigen Receptor T-cell (CAR-T)
The University of Texas MD Anderson Cancer Center held its 38th annual Polo on the Prairie event on April 27 in West Texas, raising over…
The newly appointed president of the Oncology Nursing Society (ONS) discussed healthcare policies that she and ONS will continue to advocate for in the cancer…
Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.
Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients…